Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting
Status:
Not yet recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass
Grafting trial (TOP-CABG trial) is a multicenter, randomized, double-blind, non-inferiority,
parallel controlled trial. The first aim of TOP-CABG is to investigate, comparing to dual
antiplatelet therapy (DAPT), whether de-escalated dual antiplatelet therapy (De-DAPT) is
non-inferior to dual antiplatelet therapy (DAPT) in efficacy on inhibiting great saphenous
vein (SVG) graft occlusion in patients accepting coronary artery bypassing grafting. The
second aim is to compare the risk of bleeding events between DAPT and De-DAPT.